Roche für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 851311 / ISIN: CH0012032113

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Roche Holding AG (Inhaberaktie)

18.10.23		Roche’s Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer (GlobeNewswire)
13.10.23		Late-breaking data for Roche’s BTK inhibitor fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis (GlobeNewswire)
12.10.23		New data for Roche’s OCREVUS show that after 10 years of treatment 77% of people with relapsing multiple sclerosis were free from disability progression and 92% continue to walk unaided (GlobeNewswire)
11.10.23		Roche’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions (GlobeNewswire)
10.10.23		Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies (GlobeNewswire)
04.10.23		Majority of newborn babies with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi able to sit independently after 1 year of treatment (GlobeNewswire)
02.10.23		Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD (GlobeNewswire)
07.09.23		Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardi (GlobeNewswire)
05.09.23		Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare (PR Newswire)
01.09.23		Roche’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer (GlobeNewswire)
29.08.23		Roche’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes (GlobeNewswire)
29.08.23		European Commission approves Roche’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA) (GlobeNewswire)
23.08.23		[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer (GlobeNewswire)
27.07.23		[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions’ base business; Group sales and profit reflect declining demand for COVID-19 products (GlobeNewswire)
27.07.23		[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche verzeichnet starkes Wachstum im Basisgeschäft beider Divisionen; Konzernverkäufe und -gewinn widerspiegeln rückläufige Nachfrage nach COVID-19-Produkten (GlobeNewswire)
24.07.23		Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk (GlobeNewswire)
21.07.23		CHMP recommends Roche’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA) (GlobeNewswire)
20.07.23		New clinical and real-world data for Roche’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss (GlobeNewswire)
13.07.23		Positive Phase III results for Roche’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis (GlobeNewswire)
11.07.23		European Commission approves Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma (GlobeNewswire)
30.06.23		Four-year follow up data for Roche’s Evrysdi show continued increase in number of children with a severe form of spinal muscular atrophy (SMA) able to sit, stand and walk (GlobeNewswire)
16.06.23		FDA approves Roche’s Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma (GlobeNewswire)
13.06.23		Roche awarded WHO prequalification for the cobas® HPV test, increasing access to cervical cancer screening tools in low and lower-middle income countries (GlobeNewswire)
09.06.23		New data show Roche’s subcutaneously administered crovalimab achieved disease control and was well-tolerated in people with paroxysmal nocturnal haemoglobinuria (PNH) (GlobeNewswire)
17.05.23		Roche’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis (GlobeNewswire)
09.05.23		FDA accepts application for Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO) (GlobeNewswire)
04.05.23		Roche launches Institute of Human Biology to accelerate breakthroughs in R&D by unlocking the potential of human model systems (GlobeNewswire)
26.04.23		CHMP recommends EU approval of Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma (GlobeNewswire)
26.04.23		[Ad-hoc-Mitteilung gemäss Art. 53 LR] Roche erzielt im ersten Quartal ein starkes Verkaufswachstum im Basisgeschäft beider Divisionen; Rückgang der Konzernverkäufe aufgrund der erwartungsgemäss gering (GlobeNewswire)
26.04.23		[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 (GlobeNewswire)
25.04.23		New Vabysmo data suggest greater retinal drying versus aflibercept in nAMD and DME (GlobeNewswire)
19.04.23		[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche’s Polivy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma (GlobeNewswire)
16.04.23		Roche’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study (GlobeNewswire)
13.04.23		Roche data highlights strength of ophthalmology portfolio and commitment to advancing eye care at ARVO 2023 (GlobeNewswire)
22.03.23		Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer's disease (GlobeNewswire)
20.03.23		New four year data for Roche’s Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA) (GlobeNewswire)
14.03.23		Roche Generalversammlung 2023 (GlobeNewswire)
14.03.23		Roche Annual General Meeting 2023 (GlobeNewswire)
10.03.23		FDA Advisory Committee votes in favour of the clinical benefit of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma (GlobeNewswire)
23.02.23		Roche launches two new antibodies to identify key clinical mutations in patients with brain cancer (GlobeNewswire)
10.02.23		[Ad hoc-Mitteilung gemäss Art. 53 KR] Transaktion in Roche Inhaberaktien (GlobeNewswire)
10.02.23		[Ad hoc announcement pursuant to Art. 53 LR] Transaction in Roche bearer shares (GlobeNewswire)
10.02.23		New phase III data show Roche’s Vabysmo rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion (RVO) (GlobeNewswire)
14.11.22		[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s disease (GlobeNewswire)
09.11.22		STRONG-HF study results demonstrate clear benefits for acute heart failure patients (GlobeNewswire)
03.11.22		Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs (GlobeNewswire)
27.10.22		Positive topline phase III results show Roche's Vabysmo improved vision for people living with retinal vein occlusion (RVO) (GlobeNewswire)
26.10.22		Early treatment with Roche's OCREVUS leads to reduced disease progression and healthcare costs; nine-year safety data reinforce favourable benefit-risk profile (GlobeNewswire)
24.10.22		Roche receives FDA clearance for COVID-19 PCR test for use on cobas 6800/8800 Systems (GlobeNewswire)
19.10.22		Roche to present new OCREVUS (ocrelizumab) data in multiple sclerosis and continued research into neuromyelitis optica spectrum disorder at ECTRIMS 2022 (GlobeNewswire)

Erste Seite Zurück | ... | 2 | 3 | 4 | 5 | Weiter

Newssuche

Roche Peer Group Nachrichten

17:19		GSK-Aktie profitiert deutlich: Starker Absatz von Krebsmedikamenten sorgt für Gewinnplus
17:09		Novartis übernimmt Regulus Therapeutics - Novartis-Aktie in Rot, Regulus Therapeutics-Aktie mit Kurssprung
16:04		Dow Jones 30 Industrial-Papier Johnson Johnson-Aktie: So viel Gewinn hätte ein Johnson Johnson-Investment von vor 10 Jahren abgeworfen
29.04.25		AstraZeneca-Aktie dennoch niedriger: Wachstumskurs zum Jahresstart
29.04.25		S&P 500-Titel Pfizer-Aktie: So viel Verlust hätte eine Pfizer-Investition von vor 5 Jahren eingebracht
29.04.25		Dow Jones 30 Industrial-Titel Merck-Aktie: So viel Gewinn hätte ein Investment in Merck von vor 5 Jahren eingebracht
29.04.25		Merck-Analyse: DZ BANK bewertet Merck-Aktie mit Kaufen in neuer Analyse
29.04.25		Ausblick: Pfizer legt Quartalsergebnis vor

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	30.04.2025 17:40
Kaufwert:	EUR
	Hinzufügen Speichern

Roche Aktie

WKN: 851311 / ISIN: CH0012032113

Nachrichten zu Roche Holding AG (Inhaberaktie)

Newssuche

Roche Peer Group Nachrichten

Meistgelesene Nachrichten